CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of ...

Wells Fargo analyst Yanan Zhu has assigned their bullish stance on ARCT stock, giving a Buy rating on September 19. Yanan Zhu has given his ...

Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared ...

Also on October evenings, standing high in the east-southeast is the most distinctive landmark of autumn nights: the Great ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

Discover Arcturus Therapeutics' groundbreaking patent for mRNA constructs targeting cystic fibrosis. Learn how innovative lipid formulations may transform treatment options.

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and ...

Arcturus Therapeutics (NASDAQ:ARCT), a biotechnology company specializing in infectious disease vaccines and rare disease treatments, is navigating a complex landscape of technological innovation ...

Arcturus Therapeutics (NASDAQ:ARCT), a biotechnology company specializing in infectious disease vaccines and rare disease treatments, is navigating a complex landscape of technological innovation and ...

On Wednesday, investment firm William Blair maintained its Outperform rating on Arcturus Therapeutics (NASDAQ:ARCT), a biotechnology company focused on mRNA medicines. The endorsement comes ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious ...